by adding an angiotensin II receptor blocker (ARB) to treatment with maximal recommended doses of an ACE inhibitor (ACEI) in patients with type 2 diabetes and nephropathy. Research Design and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback